Quality Control Scientist
Regeneron Pharmaceuticals
Summary
Regeneron is looking for a Quality Control Scientist in the Technical Resources Department. In this position you will perform assay development, characterization, optimization, transfer, validation, and investigations for QC. You would provide technical support, guidance and supervision for release, stability, and in-process testing and assay development.
Job description
When & where
- Monday–Friday, 8:00am–4:30pm
- Location: Rensselaer, New York, United States
Discover your role
- Performs assay development and validation for Quality Control.
- Reviews new test procedures and assays.
- Evaluates and bring in new methodologies and techniques when needed.
- Facilitate assay transfer from R&D and to business partners.
- Organize analytical assay transfer internally and externally.
- Set product specification.
- Participates in technical troubleshooting and problem investigation.
- Reviews analytical development report, assay and process validation report and other technical documents for technical correctness and regulatory compliance.
- Participates in training programs for analysts.
This role requires
A BS in Chemistry, Biochemistry, Biology, or a related field, and 3+ years of relevant experience. Experience with cell or gene therapy in a Biopharmaceutical environment is strongly preferred. In depth knowledge with HPLC based assays. Level is determined based on experience relevant to the role.
Requirements
- BS in Chemistry, Biochemistry, Biology, or a related field
- 3+ years of relevant experience
- Experience with cell or gene therapy in a Biopharmaceutical environment (strongly preferred)
- In-depth knowledge with HPLC based assays
Benefits
- Annual bonuses
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.